Post hoc analysis shows no efficacy differences in overactive bladder with cardiovascular issues, indicating good tolerance.
No significant differences in mirabegron efficacy were noted between groups with OAB with and without CRC. Low prevalence of cardiac TEAEs was noted, which indicates that mirabegron was well tolerated in both groups.
No takes yet. Share an insight, caveat, or question.
Lockefeer et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: